AceLink Presents Phase 2 Results of AL01211 for Fabry Disease
AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim data from its ongoing Phase 2 clinical study of...